NICE nixes AstraZeneca's Lynparza; Faes sets China marketing deal; Sanofi faces ERISA suit over alleged kickbacks;

> England's cost-effectiveness gatekeepers at the National Institute for Health and Care Excellence rejected AstraZeneca's ($AZN) new ovarian cancer drug Lynparza in preliminary guidance, saying it costs too much for the benefits it provides. Release | Report

> Spain's Faes Farma inked a deal with Chinese drugmaker Eddingpharma on a joint venture that will market products in China, beginning with four of Faes' drugs. Report

> A combo of two Genentech drugs, Perjeta and Herceptin, helped breast cancer patients live longer without their disease recurring compared with Herceptin plus chemo. Story

> Stockholders in Sanofi's ($SNY) group savings plan allege that the plan's administrators violated retirement plan laws by providing misledaing information about the company's alleged kickbacks to doctors, subject of a whistleblower lawsuit. Report

And Finally... Doctors are growing increasingly impatient with cancer drug shortages. Report

Suggested Articles

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.

Pfizer and Merck KGaA's immuno-oncology agent Bavencio failed another gastric cancer study, this time as a maintenance treatment after chemotherapy.

A jury ordered Biogen to pay nearly $6 million to a former sales manager who reported a colleague's misconduct and got fired a few months later.